Evoke Pharma Total Current Assets 2012-2024 | EVOK
Evoke Pharma total current assets from 2012 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
Evoke Pharma Annual Total Current Assets
(Millions of US $) |
| 2023 |
$7 |
| 2022 |
$12 |
| 2021 |
$11 |
| 2020 |
$9 |
| 2019 |
$6 |
| 2018 |
$6 |
| 2017 |
$8 |
| 2016 |
$9 |
| 2015 |
$10 |
| 2014 |
$15 |
| 2013 |
$24 |
| 2012 |
$0 |
| 2011 |
$1 |
Evoke Pharma Quarterly Total Current Assets
(Millions of US $) |
| 2024-09-30 |
$14 |
| 2024-06-30 |
$12 |
| 2024-03-31 |
$12 |
| 2023-12-31 |
$7 |
| 2023-09-30 |
$8 |
| 2023-06-30 |
$9 |
| 2023-03-31 |
$10 |
| 2022-12-31 |
$12 |
| 2022-09-30 |
$13 |
| 2022-06-30 |
$14 |
| 2022-03-31 |
$9 |
| 2021-12-31 |
$11 |
| 2021-09-30 |
$12 |
| 2021-06-30 |
$17 |
| 2021-03-31 |
$19 |
| 2020-12-31 |
$9 |
| 2020-09-30 |
$7 |
| 2020-06-30 |
$8 |
| 2020-03-31 |
$5 |
| 2019-12-31 |
$6 |
| 2019-09-30 |
$7 |
| 2019-06-30 |
$8 |
| 2019-03-31 |
$4 |
| 2018-12-31 |
$6 |
| 2018-09-30 |
$7 |
| 2018-06-30 |
$7 |
| 2018-03-31 |
$6 |
| 2017-12-31 |
$8 |
| 2017-09-30 |
$11 |
| 2017-06-30 |
$13 |
| 2017-03-31 |
$15 |
| 2016-12-31 |
$9 |
| 2016-09-30 |
$11 |
| 2016-06-30 |
$5 |
| 2016-03-31 |
$7 |
| 2015-12-31 |
$10 |
| 2015-09-30 |
$12 |
| 2015-06-30 |
$11 |
| 2015-03-31 |
$13 |
| 2014-12-31 |
$15 |
| 2014-09-30 |
$13 |
| 2014-06-30 |
$17 |
| 2014-03-31 |
$22 |
| 2013-12-31 |
$24 |
| 2013-09-30 |
$24 |
| 2013-06-30 |
$1 |
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2011-12-31 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.007B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
